Atogepant - Generic Drug Details

What are the generic drug sources for atogepant and what is the scope of patent protection?

Atogepant is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Atogepant has one hundred and forty patent family members in forty-seven countries.

One supplier is listed for this compound.

Summary for atogepant

International Patents:	140
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	23
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for atogepant
What excipients (inactive ingredients) are in atogepant?	atogepant excipients list
DailyMed Link:	atogepant at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for atogepant

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for atogepant

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Iowa	PHASE4
Patient-Centered Outcomes Research Institute	PHASE4
AbbVie	PHASE4

See all atogepant clinical trials

Pharmacology for atogepant

Drug Class	Calcitonin Gene-related Peptide Receptor Antagonist
Mechanism of Action	Calcitonin Gene-related Peptide Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for atogepant

N02CD	Calcitonin gene-related peptide (CGRP) antagonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for ATOGEPANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QULIPTA	Tablets	atogepant	10 mg, 30 mg and 60 mg	215206	6	2025-09-29

US Patents and Regulatory Information for atogepant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-003	Sep 28, 2021		RX	Yes	Yes			Y	Y
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No			Y
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No

EU/EMA Drug Approvals for atogepant

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Aquipta	atogepant	EMEA/H/C/005871Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month	Authorised	no	no	no	2023-08-11

International Patents for atogepant

Country	Patent Number	Title	Estimated Expiration
Saudi Arabia	516371613	CGRP صيغة قرص لمركبات نشطة تجاه (Tablet Formulation for CGRP-Active Compounds)
South Korea	101537877
European Patent Office	3102210
Canada	3102937

Supplementary Protection Certificates for atogepant

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2638042	C02638042/01	Switzerland		PRODUCT NAME: ATOGEPANT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69128 06.03.2024
2638042	301248	Netherlands		PRODUCT NAME: ATOGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1750 20230814
2638042	PA2023532,C2638042	Lithuania		PRODUCT NAME: ATOGEPANTAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1750 20230811
2638042	C202330039	Spain		PRODUCT NAME: ATOGEPANT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1750; DATE OF AUTHORISATION: 20230811; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1750; DATE OF FIRST AUTHORISATION IN EEA: 20230811

Atogepant Market Dynamics and Financial Trajectory

Last updated: February 13, 2026

Atogepant, developed by Pfizer, is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the preventive treatment of episodic migraine. Market dynamics revolve around its positioning within migraine therapeutics, competitive landscape, regulatory status, and potential revenue streams. Its financial trajectory depends on uptake, pricing, reimbursement policies, and clinician adoption rates.

Market Positioning and Competitive Landscape

Atogepant enters a segment dominated by CGRP antagonists, including both oral and injectable options. The primary competitors are:

• Erenumab (Aimovig) by Amgen/Novartis (Injectable)
• Fremanezumab (Ajovy) by Teva (Injectable)
• Galcanezumab (Emgality) by Eli Lilly (Injectable)
• Ubrogepant (Ubrelvy) by Allergan (Oral acute treatment)
• Rimegepant (Nurtec ODT) by Pfizer (Oral acute and preventive treatment)

Atogepant differentiates itself as the first oral CGRP antagonist approved expressly for preventive migraine therapy. Its efficacy and safety profile align with class standards, but its market share depends on clinician preference, patient compliance, and reimbursement policies.

Regulatory and Coverage Status

• FDA Approval: October 2021 for preventive episodic migraine.
• European Medicines Agency (EMA): Filed, approval anticipated based on phase 3 data.
• Insurance Coverage: Coverage levels vary by payer, influencing adoption rates. Early access programs and formulary placements directly impact sales volume.

Market Penetration and Adoption

• Initial Launch: Focused on United States, with broader geographic plans.
• Physician Prescribing Patterns: Clinicians favor oral options for ease of use, especially in patients preferring non-injectables.
• Patient Acceptance: Oral administration enhances compliance, particularly in patients averse to injections.

Revenue Forecasts and Financial Trajectory

• Sales Estimates: Analysts forecast peak annual sales of $400M-$600M in North America within 3-5 years post-launch.
• Market Share: Expected to capture 10-15% of the migraine preventative market in initial years.
• Pricing: List price around $600-$700 per month, with discounts and rebates affecting net revenue.

Key Market Drivers and Risks

• Drivers:

  • Increasing migraine prevalence (approximately 12% globally, per WHO[1])
  • Rising preference for oral medications
  • Evolving payer policies favoring outpatient, non-invasive therapies

• Risks:

  • Competition from established injectables
  • Slow uptake due to provider inertia or formulary restrictions
  • Price pressure amidst generic and biosimilar entries

Financial Outlook and Investment Implications

• Short Term: Revenue growth constrained by initial market penetration, with current estimates indicating modest sales in the first 1-2 years.
• Medium to Long Term: Potential for increased market share driven by expanded indications, new formulations, and geographic expansion.
• Partnership Opportunities: Regulatory approvals or collaborations with payers could accelerate revenue streams.
• R&D Pipeline Influence: Future formulations or combination therapies could alter competitive positioning.

Conclusion

Atogepant's market trajectory hinges on clinician acceptance, competitive dynamics, and reimbursement landscape. Early sales data suggest modest initial revenues, but projected growth aligns with increasing migraine prevalence and oral medication adoption. Its success relies on strategic positioning against injectables and expanding therapeutic indications.

Key Takeaways

• Atogepant entered a competitive migraine preventive market with an oral formulation, filling a niche unmet by injectable therapies.
• Sales forecasts target $400M–$600M in peak annual revenues within five years, contingent on market penetration.
• Reimbursement policies and clinician preferences significantly influence adoption.
• Competition, price sensitivity, and formulary access are key risks to revenue growth.
• Expansion into international markets and new indications holds potential for revenue escalation.

FAQs

1. How does atogepant compare to other CGRP preventives?
   It is an oral therapy, offering convenience over injections, with comparable efficacy and safety profiles to injectable CGRP antagonists.

2. What are the main barriers to atogepant's market growth?
   Reimbursement hurdles, clinician familiarity with existing treatments, and competition from injectable options.

3. What is the expected timeline for peak sales?
   Between 3 to 5 years post-launch, with peak revenues around $400M–$600M annually in the US.

4. Are there expansion opportunities beyond episodic migraine?
   Yes, ongoing trials explore chronic migraine and other off-label uses, which could broaden the target patient population.

5. What pricing strategies could influence revenue?
   Pricing around $600–$700/month, coupled with rebates and formulary negotiations, will significantly affect net sales and market share.

---

Citations

[1] World Health Organization. "Migraine Fact Sheet." Available at: https://www.who.int/news-room/fact-sheets/detail/migraine